cas 114778-50-6|| where to buy (R)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine

Produktname:(R)-O-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)hydroxylamine

IUPAC Name:O-{[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl}hydroxylamine

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM122019-1g	in stock	ȁǊǧ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 114778-50-6 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:114778-50-6; Molekulare Formel:C6H13NO3; Schmelzpunkt:-; SMILES-Code:NOC[C@@H]1OC(C)(C)OC1; Dichte:

: Katalognummer:CM122019; Molekulargewicht:147.17; Siedepunkt:; Mdl-Nr.:MFCD09263188; Lagerung:Store at 2-8°C.

: Dioxolanes; Dioxolane is a heterocyclic acetal with the formula (CH2)2O2CH2. It is related to tetrahydrofuran by exchanging an oxygen for the CH2 group. The isomer 1,2-dioxolane (in which the two oxygen centers are adjacent) is a peroxide. 1,3-Dioxolane is used as solvent and comonomer in polyacetal. The dioxolane-type and their hydrogenolysis can provide very valuable partially protected building blocks either for oligosaccharide syntheses or sugar transformations.

: Alicyclic Heterocycles; When the ends of the chains are joined together into a ring, cyclic compounds result; such substances often are referred to as carbocyclic or alicyclic compounds. Substitution of one or more of the ring carbon atoms in the molecules of a carbocyclic compound with a heteroatom gives a heterocyclic compound.

: Mirdametinib; SpringWorks Therapeutics announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for mirdametinib, an investigational MEK inhibitor, in pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The NDA submission includes data from the Phase 2b ReNeu trial. The primary endpoint was confirmed objective response rate (ORR). The BICR-confirmed objective response rate was 52% in pediatric patients and 41% in adult patients. Mirdametinib treatment showed deep and durable responses and demonstrated significant improvements in key secondary patient-reported outcome measures.